Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study

Journal of Clinical Pathology

Volumn 67, Issue 1, 2014, Pages 33-39

  Lee, Jae Seok ^a   Lim, Sun Min ^a   Rha, Sun Young ^a   Roh, Jae Kyung ^a   Cho, Yong Jin ^a   Shin, Kyu Ho ^a   Yang, Woo Ik ^a   Kim, Se Hoon ^a   Kim, Hyo Song ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895064596     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201655     Document Type: Article

References (19)

1. Weiss SW, Goldblum JR. Enzinger and Weiss's soft tissue tumors. 5th edn. Mosby Press, 2008:595-9.
2. Newton WA Jr, Gehan EA, Webber BL, et al . Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an intergroup rhabdomyosarcoma study. Cancer 1995;76:1073-85.
3. Meza JL, Anderson J, Pappo AS, et al . Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006;24:3844-51. (Pubitemid 46630730)
4. McDowell HP, Foot AB, Ellershaw C, et al. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 2010;46:1588-95.
5. Kasprzycka M, Marzec M, Liu X, et al. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 2006;103:9964-9. (Pubitemid 43993606)
6. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96:4319-27.
7. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17. (Pubitemid 46815090)
8. Cessna MH, Zhou H, Sanger WG, et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 2002;15:931-8.
9. Salido M, Pijuan L, Martinez-Aviles L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011;6:21-7.
10. De Brouwer S, De Preter K, Kumps C, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4353-62.
11. van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol 2012;30:308-15.
12. Li XQ, Hisaoka M, Shi DR, et al. Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. Hum Pathol 2004;35:711-21. (Pubitemid 38881081)
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
14. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33.
15. Fletcher CDM, Mertens F. Pathology and genetics of tumours of soft tissue and bone. In: Christopher D.M. Flecther, K. Krishnan Unni, Fredrik Mertens, eds. World Health Organization classification of tumours. France: IARC Press, 2002:146-52.
16. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394-404. (Pubitemid 27080004)
17. Corao DA, Biegel JA, Coffin CM, et al. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol 2009;12:275-83.
18. Bresler SC, Wood AC, Haglund EA, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra114.
19. Kalai Khadija NA, Lueza B, Commo F, et al. ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report [abstract]. J Clin Oncol 2012;30(Suppl 10556). http://meetinglibrary. asco.org/content/ 98912-114